A new study conducted by researchers at Queen Elizabeth Hospital Birmingham in Birmingham, Great Britain, evaluated outcomes and toxicity associated with stereotactic radiotherapy in patients with ...
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy ...
July 19, 2006 –- Patients with early-stage non–small cell lung cancer who are not candidates for surgery now have other noninvasive and potentially lifesaving options. In a paper published in the July ...
Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...
Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy A consecutive sample of 400 patients completed the European Organisation for Research and ...
Exploring the evolving therapeutic landscape of stage IV lung squamous cell carcinoma: A 13-year single center experience. Evaluating the safety and effectiveness of cemiplimab in combination with ...
A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced ...
SAN FRANCISCO ― There was no significant increase in late toxicity when stereotactic body radiation therapy (SBRT) was used in the treatment of early-stage ― but inoperable ― non–small-cell lung ...
Shame can shape how early patients get diagnosed, and how aggressively they pursue treatment, if at all. In a 2014 study, Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback